@article {Limaye2022.05.11.22274934, author = {Sewanti Limaye and Simon Chowdhury and Nitesh Rohatgi and Anantbhushan Ranade and Nelofer Syed and Johann Riedemann and Raymond Page and Darshana Patil and Dadasaheb Akolkar and Vineet Datta and Revati Patil and Kiran Bendale and Pooja Fulmali and Pradeep Fulmali and Sachin Apurwa and Stefan Schuster and Sudha S Murthy and Chirantan Bose and Jinumary John and Ajay Srinivasan and Rajan Datar}, title = {Accurate Prostate Cancer Detection based on Circulating Tumor Cell Profiling}, elocation-id = {2022.05.11.22274934}, year = {2022}, doi = {10.1101/2022.05.11.22274934}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Evaluation of serum prostate specific antigen (PSA) is a part of standard prostate cancer diagnostic work-up in symptomatic males as well as for elective prostate cancer screening in asymptomatic males. The low specificity of serum PSA leading to an inability to effectively differentiate prostate cancer from benign prostate conditions is a persistent clinical challenge. Further, the low sensitivity of serum PSA leading to false negatives can miss high-grade / aggressive prostate cancers.Objective We describe a non-invasive prostate cancer detection test based on functional enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-CTCs) from blood samples and their identification via immunostaining for pan-cytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM) and common leucocyte antigen (CD45).Design, Setting, and Participants The analytical validation studies used VCaP reference prostate cancer cell line to evaluate the performance characteristics of the test. The clinical performance characteristics of the test were first evaluated in a case-control study with 160 known prostate cancer cases and 800 healthy males. A prospective clinical study was performed with samples from 210 suspected cases of prostate cancer.Outcome Measurements and Statistical Analysis Analytical validation established analyte stability as well as acceptable performance characteristics. The test showed 100\% specificity and 100\% sensitivity to differentiate prostate cancer cases from healthy individuals in the case control study and 91.2\% sensitivity and 100\% specificity to differentiate prostate cancers from benign prostate conditions in the prospective clinical study.Results and Limitations The test accurately detects PrAD-CTCs with high sensitivity and specificity irrespective of stage or grade (Gleason score), which translates into low risks of false negatives or overdiagnosis. The test does not detect minor non-adenocarcinoma subtypes of prostate cancer.Conclusions The high accuracy of the test offers advantages over PSA based prostate cancer detection.Competing Interest StatementSewanti Limaye, Simon Chowdhury, Nitesh Rohatgi, Anantbhushan Ranade, Nelofer Syed, Johann Riedemann and Raymond Page have no competing interests. Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Revati Patil, Kiran Bendale, Pooja Fulmali, Pradeep Fulmali, Sachin Apurwa, Stefan Schuster, Sudha S Murthy, Chirantan Bose, Jinumary John and Ajay Srinivasan are employees of the Study Sponsor. Rajan Datar is the founder of the Study Sponsor.Funding StatementNo external funding was obtained for this study. The entire study was funded by the Study Sponsor (Datar Cancer Genetics).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All biological samples were obtained from participants in three studies, TRUEBLOOD (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879), ProState (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31713) and RESOLUTE (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733). All studies were approved by Datar Cancer Genetics Limited Institutional Ethics Committee. All participants provided written informed consent. All studies were performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are included in the manuscript and its Supplementary Information file.}, URL = {https://www.medrxiv.org/content/early/2022/05/16/2022.05.11.22274934}, eprint = {https://www.medrxiv.org/content/early/2022/05/16/2022.05.11.22274934.full.pdf}, journal = {medRxiv} }